Overview

Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, open label study, aiming to evaluate the efficacy of beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg nebulized), on airway resistance and reactances (measured with Rint and FOT techniques) in children with recurrent wheezing, aged 2-5 years. In addition, clinic score as frequency of symptoms and exacerbations, will be assessed.
Phase:
Phase 4
Details
Lead Sponsor:
Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy
Istituto per la Ricerca e l'Innovazione Biomedica
Treatments:
Beclomethasone